HIV-1 reverse transcriptase inhibitors have long been central to antiretroviral therapy, effectively impeding the enzyme responsible for converting viral RNA into DNA – a pivotal step in HIV ...
At the 12th International HIV Drug Resistance Workshop, held June 10-14, 2003, in Los Cabos, Mexico, investigators from around the world provided the latest results from studies of resistance topics ...
Pretreatment drug resistance (PDR) in patients with HIV varies by subtype, affecting antiretroviral therapy implementation and first-line treatment efficacy. In Hangzhou, 8.4% of newly diagnosed HIV ...
RALEIGH, NC, USA, May 2, 2023/EINPresswire.com/ -- Collaborations Pharmaceuticals, Inc. (CPI) with collaborators at the Research Center of Biotechnology RAS, Moscow ...
Use of nucleoside reverse transcriptase inhibitors (NRTIs), but not other medications for HIV, was associated with a significantly reduced risk for Alzheimer’s disease (AD) in an analysis of two ...
For the treatment of HIV infection, non-nucleoside reverse transcriptase inhibitors (NNRTIs) are used to prevent viral replication by binding to a pocket near the polymerase active site of HIV-1 ...
Retrotransposons could have a main role in the development of drug resistance in response to cancer treatment, according to a new study out of the Roswell Park Comprehensive Cancer Center. The ...
After 48 weeks of treatment, TPN-101 reduced the levels of neurofilament light chain and interleukin 6, both key biomarkers of neurodegeneration and neuroinflammation in PSP. The Food and Drug ...
HIV-1 reverse transcriptase inhibitors remain a cornerstone of antiretroviral therapy, targeting the enzyme responsible for converting viral RNA into DNA. This class of drugs, particularly nucleoside ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback